Pliant Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company, announced participation in virtual fireside chats at upcoming investor conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference will feature a pre-recorded chat on November 22, 2021, at 10:00am ET. The Evercore ISI 4th Annual HealthconX Conference will occur on November 30, 2021, at 3:30pm ET. Presentations can be accessed on Pliant's website, with audio available for 90 days post-event. Pliant is focused on developing therapies for fibrosis, including their lead candidate, PLN-74809.

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, along with members of Pliant’s senior management team, will participate in virtual fireside chats at the following investor conferences:

• Piper Sandler 33rd Annual Virtual Healthcare Conference – Pliant’s pre-recorded fireside chat will be available on Monday, November 22, 2021, at 10:00am ET
• Evercore ISI 4th Annual HealthconX Conference – Pliant will participate in a fireside chat on Tuesday, November 30, 2021, at 3:30pm ET

Interested parties can access these presentations from the Investor Relations’ Events & Presentation page of Pliant’s website at https://ir.pliantrx.com/news-and-events/events-and-presentations with an audio archive of these fireside chats available for 90 days from the time they are made available.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of α_vß₆ and α_vß₁ integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of α_vß₁ for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

FAQ

What are the details of Pliant Therapeutics' virtual fireside chats scheduled for November 2021?

Pliant Therapeutics will have a pre-recorded chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00am ET, and a live chat at the Evercore ISI 4th Annual HealthconX Conference on November 30, 2021, at 3:30pm ET.

How can I access the presentations from Pliant Therapeutics' investor conferences?

The presentations will be available on Pliant Therapeutics' Investor Relations Events & Presentation page, with audio archives accessible for 90 days after the events.

What is PLN-74809, the lead candidate of Pliant Therapeutics?

PLN-74809 is an oral small molecule dual selective inhibitor of αvβ6 and αvβ1 integrins, currently being developed for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).

Has PLN-74809 received any special designations from the FDA?

Yes, PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both idiopathic pulmonary fibrosis and primary sclerosing cholangitis.